Side-by-Side In 2013, the U.S. Food and Drug Administration (FDA) made an announcement regarding widely used sleep drugs containing the active ingredient zolpidem. It contained the statement: "Since women eliminate zolpidem from their bodies more slowly than men, the FDA has notified the manufacturers that the recommended dose should be lowered for women." Macmillan Learning O A lurking variable was later revealed, leading the to issue a notification. What is this lurking variabl blood type Olevel of insomnia O drug safety gender 1 U.S. Food and Drug Administration (FDA), "FDA requiring lower recommended dose for certain sleep drugs containing zolpidem," January 10, 2013, www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm334798.ht m. What is the reason cited explaining the impact of lurking variable? The FDA is recalling the drug zolpidem. The FDA cited that women eliminate zolpid from their bodies more slowly than men. The FDA cited that women eliminate zolpid from their bodies more quickly than men. The FDA cited that men eliminate zolpidem their bodies more slowly than women.